Portfolio company Verve Therapeutics was acquired by Eli Lilly in June 2025.
Verve Therapeutics is a cardiovascular gene editing company focused on developing groundbreaking, single-course gene editing medicines to combat cardiovascular disease
Verve Therapeutics is a cardiovascular gene editing company focused on developing groundbreaking, single-course gene editing medicines to combat cardiovascular disease.